June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Five-year results of a population treated in "real life" with PRN regimen for an exudative age-related macular degeneration: ELOUAN 2 registry
Author Affiliations & Notes
  • Frederic Queguiner
    Ophtalmology, hopital saint joseph, Marseille, France
  • Maud Righini
    Ophtalmology, hopital saint joseph, Marseille, France
  • Jean Christophe Courjaret
    Ophtalmology, hopital saint joseph, Marseille, France
  • Footnotes
    Commercial Relationships   Frederic Queguiner, None; Maud Righini, None; Jean Christophe Courjaret, None
  • Footnotes
    Support  Grant support from Novartis france SAS
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 414. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Frederic Queguiner, Maud Righini, Jean Christophe Courjaret; Five-year results of a population treated in "real life" with PRN regimen for an exudative age-related macular degeneration: ELOUAN 2 registry. Invest. Ophthalmol. Vis. Sci. 2017;58(8):414.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Exudative AMD, a frequent disease related to the population aging, is one of the leading causes of legal blindness and represents today a major public health problem. In the literature few long-term results (> 5 years) are available for this type of population. We aimed to present the results of a population of patients treated in real life for 5 years.

Methods : In this retrospective, monocentric registry, patients with exudative AMD treated in real life with intravitreal injections of anti-VEGF (Ranibizumab) were followed by PRN regimen with monthly control visits (CV). The primary objective was to study changes in visual acuity (VA) over time (initial VA, and VA at: 6, 12, 18, 24, 30, 36, 42, 48 months). The secondary objective was to assess whether the number of CV and Injection visits (IV) throughout follow-up were good predictor of VA evolution over time.

Results : The studied population (109 patients and 131 eyes) had a usual female prevalence (64%) and a mean age of 78.4 ± 7.7 years.
VA significantly increased during the first 6 months, with a delta ETDRS of 4.2 ± 15.2 letters (p = 0.0288). VA declined thereafter until the end of the follow-up, but without any statistical significance between the different controls (table 1).
The mean number of CV and IV decreased all along the follow-up and this decrease was significant most of the time (table 2).

Conclusions : Anti-VEGFs IVTs represent a reliable treatment for exudative AMD, even in the long term (at 5 years). PRN regimen with regular follow-up and treatment is necessary to stabilize patients' AV over time. The follow-up should be adapted by the ophthalmologist to the progress of each patient, in order to avoid over or under treatment, which, in both cases, could deleterious to the final result.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Table 1: Statistical analysis of visual acuity (ETDRS an SNELLEN) at each time of the follow-up compared to the previous time

Table 1: Statistical analysis of visual acuity (ETDRS an SNELLEN) at each time of the follow-up compared to the previous time

 

Table 2: Statistical analysis of mean number of control and injection visits for each year of follow-up compared to previous year


Table 2: Statistical analysis of mean number of control and injection visits for each year of follow-up compared to previous year


×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×